metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
	cemiplimab vs. Standard of Care (SoC)	1	-1277 [-2034; -519] /10000 70/283 vs. 105/280	-1841 [-2632; -1051] /10000 147/283 vs. 197/280	-
	durvalumab alone vs. Standard of Care (SoC)	1	-1275 [-2235; -316] /10000 108/163 vs. 128/162	-411 [-1431; 610] /10000 106/163 vs. 112/162	-
	nivolumab alone vs. Standard of Care (SoC)	2	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
	pembrolizumab alone vs. Standard of Care (SoC)	4	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-